Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)

NCT03833427 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

32

Enrollment

INDUSTRY

Sponsor class

Stopped Business Reasons

Conditions

Advanced/Metastatic Solid Tumors

Interventions

DRUG: Selumetinib
DRUG: Pembrolizumab

Sponsor

Merck Sharp & Dohme LLC